The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study

The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study

Abstract Background Real‐world application of osimertinib with antiangiogenic agents in non‐small cell lung cancer (NSCLC) is common, but the efficacy data are rarely reported. Methods To obtain an objective efficacy report of different real‐world treatment models of osimertinib and antiangiogenic a...

Full description

Bibliographic Details
Main Authors: Yu Feng, Liling Huang, Haohua Zhu, Le Tang, Xingsheng Hu, Yuankai Shi
Format: Article
Language:English
Published: Wiley 2022-09-01
Series:Thoracic Cancer
Subjects:
antiangiogenic agents
non‐small cell lung cancer
osimertinib
resistance
Online Access:https://doi.org/10.1111/1759-7714.14603

Similar Items

Similar Items